Importance: Although guidelines for vitamin D supplementation in infants have been widely implemented, they are mostly based on studies focusing on prevention of rickets. The optimal dose for bone strength and infection prevention in healthy infants remains unclear. Objective: To determine whether daily supplementation with 1200 IU of vitamin D3 increases bone strength or decreases incidence of infections in the first 2 years of life compared with a dosage of 400 IU/d. Design, Setting, and Participants: A randomized clinical trial involving a random sample of 975 healthy term infants at a maternity hospital in Helsinki, Finland. Study recruitment occurred between January 14, 2013, and June 9, 2014, and the last follow-up was May 30, 2016. Data analysis was by the intention-to-treat principle. Interventions: Randomization of 489 infants todaily oral vitamin D3 supplementationof 400 IU and 486 infants to 1200 IU from age 2 weeks to 24 months. Main Outcomes and Measures: Primary outcomes were bone strength and incidence of parent-reported infections at 24 months. Results: Of the 975 infants who were randomized, 485 (49.7%) were girls and all were of Northern European ethnicity. Eight hundred twenty-three (84.4%) completed the 24-month follow-up. We found no differences between groups in bone strength measures, including bone mineral content (mean difference, 0.4 mg/mm; 95% CI, -0.8 to 1.6), mineral density (mean difference, 2.9 mg/cm3; 95% CI, -8.3 to 14.2), cross-sectional area (mean difference, -0.9 mm2; 95% CI, -5.0 to 3.2), or polar moment of inertia (mean difference, -66.0 mm4, 95% CI, -274.3 to 142.3). Incidence rates of parent-reported infections did not differ between groups (incidence rate ratio, 1.00; 95% CI, 0.93-1.06). At birth, 914 of 955 infants (95.7%) were vitamin D sufficient (ie, 25-hydroxyvitamin D [25(OH)D] concentration ≥20.03 ng/mL). At 24 months, mean 25(OH)D concentration was higher in the 1200-IU group than in the 400-IU group (mean difference, 12.50 ng/mL; 95% CI, 11.22-13.78). Conclusions and Relevance: A vitamin D3 supplemental dose of up to 1200 IU in infants did not lead to increased bone strength or to decreased infection incidence. Daily supplementation with 400 IU vitamin D3 seems adequate in maintaining vitamin D sufficiency in children younger than 2 years. Trial Registration: ClinicalTrials.gov Identifier: NCT01723852.
RCT Entities:
Importance: Although guidelines for vitamin D supplementation in infants have been widely implemented, they are mostly based on studies focusing on prevention of rickets. The optimal dose for bone strength and infection prevention in healthy infants remains unclear. Objective: To determine whether daily supplementation with 1200 IU of vitamin D3 increases bone strength or decreases incidence of infections in the first 2 years of life compared with a dosage of 400 IU/d. Design, Setting, and Participants: A randomized clinical trial involving a random sample of 975 healthy term infants at a maternity hospital in Helsinki, Finland. Study recruitment occurred between January 14, 2013, and June 9, 2014, and the last follow-up was May 30, 2016. Data analysis was by the intention-to-treat principle. Interventions: Randomization of 489 infants to daily oral vitamin D3 supplementation of 400 IU and 486 infants to 1200 IU from age 2 weeks to 24 months. Main Outcomes and Measures: Primary outcomes were bone strength and incidence of parent-reported infections at 24 months. Results: Of the 975 infants who were randomized, 485 (49.7%) were girls and all were of Northern European ethnicity. Eight hundred twenty-three (84.4%) completed the 24-month follow-up. We found no differences between groups in bone strength measures, including bone mineral content (mean difference, 0.4 mg/mm; 95% CI, -0.8 to 1.6), mineral density (mean difference, 2.9 mg/cm3; 95% CI, -8.3 to 14.2), cross-sectional area (mean difference, -0.9 mm2; 95% CI, -5.0 to 3.2), or polar moment of inertia (mean difference, -66.0 mm4, 95% CI, -274.3 to 142.3). Incidence rates of parent-reported infections did not differ between groups (incidence rate ratio, 1.00; 95% CI, 0.93-1.06). At birth, 914 of 955 infants (95.7%) were vitamin D sufficient (ie, 25-hydroxyvitamin D [25(OH)D] concentration ≥20.03 ng/mL). At 24 months, mean 25(OH)D concentration was higher in the 1200-IU group than in the 400-IU group (mean difference, 12.50 ng/mL; 95% CI, 11.22-13.78). Conclusions and Relevance: A vitamin D3 supplemental dose of up to 1200 IU in infants did not lead to increased bone strength or to decreased infection incidence. Daily supplementation with 400 IU vitamin D3 seems adequate in maintaining vitamin D sufficiency in children younger than 2 years. Trial Registration: ClinicalTrials.gov Identifier: NCT01723852.
Authors: Rosemary L Schleicher; Maya R Sternberg; David A Lacher; Christopher T Sempos; Anne C Looker; Ramon A Durazo-Arvizu; Elizabeth A Yetley; Madhulika Chaudhary-Webb; Khin L Maw; Christine M Pfeiffer; Clifford L Johnson Journal: Am J Clin Nutr Date: 2016-07-06 Impact factor: 7.045
Authors: Laura Toivonen; Linnea Schuez-Havupalo; Sinikka Karppinen; Tamara Teros-Jaakkola; Maris Rulli; Jussi Mertsola; Matti Waris; Ville Peltola Journal: Pediatrics Date: 2016-09 Impact factor: 7.124
Authors: Craig F Munns; Nick Shaw; Mairead Kiely; Bonny L Specker; Tom D Thacher; Keiichi Ozono; Toshimi Michigami; Dov Tiosano; M Zulf Mughal; Outi Mäkitie; Lorna Ramos-Abad; Leanne Ward; Linda A DiMeglio; Navoda Atapattu; Hamilton Cassinelli; Christian Braegger; John M Pettifor; Anju Seth; Hafsatu Wasagu Idris; Vijayalakshmi Bhatia; Junfen Fu; Gail Goldberg; Lars Sävendahl; Rajesh Khadgawat; Pawel Pludowski; Jane Maddock; Elina Hyppönen; Abiola Oduwole; Emma Frew; Magda Aguiar; Ted Tulchinsky; Gary Butler; Wolfgang Högler Journal: J Clin Endocrinol Metab Date: 2016-01-08 Impact factor: 5.958
Authors: Mary Aglipay; Catherine S Birken; Patricia C Parkin; Mark B Loeb; Kevin Thorpe; Yang Chen; Andreas Laupacis; Muhammad Mamdani; Colin Macarthur; Jeffrey S Hoch; Tony Mazzulli; Jonathon L Maguire Journal: JAMA Date: 2017-07-18 Impact factor: 56.272
Authors: Adrian R Martineau; David A Jolliffe; Richard L Hooper; Lauren Greenberg; John F Aloia; Peter Bergman; Gal Dubnov-Raz; Susanna Esposito; Davaasambuu Ganmaa; Adit A Ginde; Emma C Goodall; Cameron C Grant; Christopher J Griffiths; Wim Janssens; Ilkka Laaksi; Semira Manaseki-Holland; David Mauger; David R Murdoch; Rachel Neale; Judy R Rees; Steve Simpson; Iwona Stelmach; Geeta Trilok Kumar; Mitsuyoshi Urashima; Carlos A Camargo Journal: BMJ Date: 2017-02-15
Authors: Anu Kaskinen; Benjamin Ayeboa-Sallah; Tiina Teivaanmäki; Elina Wärnhjelm; Liisa Korhonen; Otto Helve Journal: J Med Internet Res Date: 2018-12-14 Impact factor: 5.428
Authors: David A Jolliffe; Carlos A Camargo; John D Sluyter; Mary Aglipay; John F Aloia; Davaasambuu Ganmaa; Peter Bergman; Arturo Borzutzky; Camilla T Damsgaard; Gal Dubnov-Raz; Susanna Esposito; Clare Gilham; Adit A Ginde; Inbal Golan-Tripto; Emma C Goodall; Cameron C Grant; Christopher J Griffiths; Anna Maria Hibbs; Wim Janssens; Anuradha Vaman Khadilkar; Ilkka Laaksi; Margaret T Lee; Mark Loeb; Jonathon L Maguire; Paweł Majak; David T Mauger; Semira Manaseki-Holland; David R Murdoch; Akio Nakashima; Rachel E Neale; Hai Pham; Christine Rake; Judy R Rees; Jenni Rosendahl; Robert Scragg; Dheeraj Shah; Yoshiki Shimizu; Steve Simpson-Yap; Geeta Trilok Kumar; Mitsuyoshi Urashima; Adrian R Martineau Journal: medRxiv Date: 2020-11-25
Authors: Nicklas Brustad; Bo L Chawes; Jonathan Thorsen; Martin Krakauer; Jessica Lasky-Su; Scott T Weiss; Jakob Stokholm; Klaus Bønnelykke; Hans Bisgaard Journal: EClinicalMedicine Date: 2021-12-24
Authors: Karin Amrein; Mario Scherkl; Magdalena Hoffmann; Stefan Neuwersch-Sommeregger; Markus Köstenberger; Adelina Tmava Berisha; Gennaro Martucci; Stefan Pilz; Oliver Malle Journal: Eur J Clin Nutr Date: 2020-01-20 Impact factor: 4.016